2018 CALENDAR OF EVENTS
ONEINFORTY SHABBAT TALK
Friday, October 26th at 7:00 p.m.
Temple Beth Sholom of Nantasket
600 Nantasket Ave.
Hull, MA 02045
ONEINFORTY SYMPOSIUM REGISTER TODAY!
Knowledge is Empowering:
Understanding the Jewish - Cancer Connection
Wednesday, November 7th, 7:00 - 9:00 p.m.
25 Canton St.
Sharon, MA 02067
Temple Sinai, located in Sharon, Massachusetts, will host this Oneinforty symposium to educate the community about Ashkenazi Jews' one-in-forty risk of inheriting a BRCA gene mutation. Having a BRCA gene mutation significantly increases one's risk of developing breast, ovarian, prostate and other cancers that, in many cases, can be prevented or detected early.
Panelists will discuss genetic counseling, the rationale for testing for BRCA gene mutations, managing cancer risk and resources available for those who carry BRCA gene mutations. You will also learn about the new BRCA Founder Outreach (BFOR) Study being conducted by Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Memorial Sloan Kettering, Cedars-Sinai Medical Center, Penn Medicine and the Basser Center for BRCA. Jewish individuals who have a BRCA gene mutation will also share their stories. Following presentations by each of the panelists listed below, there will be a Q&A session.
Betty Cooperstein, LICSW
In private practice in Brookline & Wayland, MA
Founder & Executive Director
BRCA-positive ovarian cancer survivor
Whitfield B. Growdon, MD
Center for Gynecologic Oncology
Massachusetts General Hospital
Joi Morris, JD
Senior Vice President, Alliances & General Counsel
Director of National Outreach
This symposium is free-of-charge and open to the general public. Kosher refreshments will be served.
Questions? Please contact Lauren Corduck at 617-823-3630 or firstname.lastname@example.org
Presented by Oneinforty, a nonprofit organization that raises awareness of the one-in-forty risk to Ashkenazi Jews of inheriting BRCA gene mutations and provides the support individuals and families need to effectively manage their cancer risk.